參考價	￥ 1024

信號通路

MedChemExpress (M

CAS	1110813-31-4	純度	99.74%
分子量	469.94	分子式	C??H??ClFN?O?
供貨周期	現貨	規格	10 mM * 1 mL
貨號	HY-13272	應用領域	醫療衛生,化工,生物產業,制藥/生物制藥

Dacomitinib (PF-00299804) 是一種特異，不可逆的 ERBB 家族抑制劑，作用于 EGFR，ERBB2 和 ERBB4 的 IC50 分別為 6 nM，45.7 nM 和 73.7 nM。

詳細介紹

MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

Dacomitinib

CAS No. : 1110813-31-4

MCE 國際站：Dacomitinib

產品活性：Dacomitinib (PF-00299804) 是一種特異，不可逆的 ERBB 家族抑制劑，作用于 EGFR，ERBB2 和 ERBB4 的 IC₅₀ 分別為 6 nM，45.7 nM 和 73.7 nM。

研究領域：JAK/STAT Signaling | Protein Tyrosine Kinase/RTK | Apoptosis

作用靶點：EGFR | Apoptosis

In Vitro: Dacomitinib (PF00299804) effectively inhibits the in vitro kinase activity of wild-type EGFR (IC50=6 nM)with similar efficacy. Dacomitinib also effectively inhibits wild-type ERBB2 with IC₅₀ of 45.7 nM. In H441, an IC₅₀ is reached with Dacomitinib but only at a very high concentration (4 μM) and likely reflects off-target effects. In cell lines wild-type for both EGFR and K-ras (H322, H1819, and Calu-3), ZD1839 and Dacomitinib both effectively inhibit growth of H1819 and Calu-3 cells but not of H322 cells. Dacomitinib is a pan-ERBB inhibitor and most EGFR mutant cell lines express multiple ERBB family members, the effects on EGFR phosphorylation could potentially be indirect. Dacomitinib inhibits EGFR phosphorylation in all of the different EGFR T790M proteins whereas ZD1839 is ineffective even at 10 μM. In the NIH3T3 cells, phosphorylation of EGFR L858R/T790M is completely inhibited by 1 nM Dacomitinib, whereas 100 nM or greater is required to inhibit EGFR WT/T790M or Del/T790M. The HER2-amplified cell lines are most sensitive to growth inhibition by Dacomitinib (IC₅₀<1 μM in 14 of 16 lines; 87.5%) as compared with 5 of 28 (17.9%) of HER2-nonamplified lines (excluding immortalized lines).

In Vivo: To evaluate the efficacy of Dacomitinib, xenografts in nu/nu mice are generated using HCC827 GFP and HCC827 Del/T790M cells and treated the mice with Dacomitinib. Dacomitinib (10 mg/kg/d by daily oral gavage) effectively inhibits the growth of HCC827 GFP xenografts. In contrast, HCC827 Del/T790M xenografts are resistant to ZD1839, whereas Dacomitinib treatment is substantially more effective at inhibiting growth of this xenograft model.